Molecular Test Assessments

Molecular Test Assessments are comprehensive health technology assessments of molecular tests across a range of conditions and applications. Each report provides a clear, objective view of the science behind a specific molecular test, the clinical evidence supporting the test, the manufacturer, an explanation of how the test is used in clinical practice, and appropriate patient selection criteria.

These reports include the Hayes Rating to indicate the overall strength and direction of the body of evidence for the molecular test. Molecular Test Assessments provide evidence-based support for the development of coverage policy, utilization management, and evidence-based clinical practices. Reports are reviewed annually up to 5 years post publication to determine if there is new literature or evidence that would impact a change in rating and warrant an updated report.

FirstSightCRC (CellMax Life)

The report evaluates the analytical validity, clinical validity, and clinical utility of the FirstSightCRC test, a liquid biopsy test that detects and analyzes circulating tumor cells (CTCs) and is intended to predict the likelihood of having precancerous adenomatous polyps or colorectal cancer (CRC) in patients eligible for CRC screening.

ColonSentry (Stage Zero Life Sciences)

The report evaluates the analytical validity, clinical validity, and clinical utility of the ColonSentry liquid biopsy test, a gene expression assay intended to estimate the current relative risk of having colorectal cancer (CRC) for patients eligible for CRC screening.